WO2002046758A1 - Procede de magnetisation de marqueurs chimiques ou biologiques - Google Patents
Procede de magnetisation de marqueurs chimiques ou biologiques Download PDFInfo
- Publication number
- WO2002046758A1 WO2002046758A1 PCT/FR2001/003887 FR0103887W WO0246758A1 WO 2002046758 A1 WO2002046758 A1 WO 2002046758A1 FR 0103887 W FR0103887 W FR 0103887W WO 0246758 A1 WO0246758 A1 WO 0246758A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- markers
- particles
- magnetic particles
- biological
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000000126 substance Substances 0.000 title claims abstract description 13
- 239000000090 biomarker Substances 0.000 title claims abstract description 10
- 239000006249 magnetic particle Substances 0.000 claims abstract description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 2
- 230000005670 electromagnetic radiation Effects 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 238000004166 bioassay Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 210000003743 erythrocyte Anatomy 0.000 description 21
- 230000005291 magnetic effect Effects 0.000 description 13
- 239000003550 marker Substances 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000005298 paramagnetic effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 5
- 230000005415 magnetization Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000005294 ferromagnetic effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
Definitions
- the invention relates to a method of magnetizing chemical or biological markers as well as to the use of said biological markers in a biological analysis test.
- Immunological analysis tests then typically relate to the search, in blood or in a blood component, for antigens present on the surface of red blood cells using magnetized anti-erythrocyte antibodies (for example erythrocyte typing) or the anti-erythrocyte antibody research using magnetized red cells on which specific antigens are present and / or attached.
- magnetized anti-erythrocyte antibodies for example erythrocyte typing
- anti-erythrocyte antibody research using magnetized red cells on which specific antigens are present and / or attached.
- This type of process uses magnetic particles, the surface of which has been functionalized so as to form bonds with a specific marker.
- the invention therefore aims to remedy all of these drawbacks by proposing in particular a method of direct magnetization of particulate and / or figured elements without the intermediary of molecules recognizing for example structures of antigen and / or antibody type and this without masking and / or modifying the structures to be implemented, for example during a biological analysis test.
- the invention provides a method of magnetizing chemical or biological markers using magnetic particles, said method comprising the steps consisting in: - activating the magnetic particles so as to modify their state of surface ; - bringing the activated magnetic particles into contact with the markers so as to create non-specific bonds between them.
- the invention proposes the use of magnetized biological markers by the implementation of such a method as reagents or analytes in a biological analysis test.
- the method makes it possible to magnetize markers using magnetic particles by creating non-specific bonds between them.
- the markers can be chemical, for example in molecular form, or biological, for example in cellular form, and the magnetic particles are for example beads of compatible polymers which are loaded with a magnetic material.
- a marker is in contact with its immediate environment via its surface and, in the case of a cellular element, through its membrane.
- the cell has, in a way, an arsenal of possible links with various surrounding molecular structures, such as magnetic particles.
- the cell is able to establish links with elements as well so:
- a receptor structure of the membrane is recognized by an effector which is specific to it (for example in the case of hormone-receptor bonds or antigen-antibody bonds);
- This cell membrane the first meeting structure of the cell, will therefore be the site of important interactions both for the cell and for the external environment. It carries on its surface the majority of molecular structures for identifying the cell, but also structures capable of specifically or not binding to foreign molecules.
- the markers are red blood cells whose cell membrane is the support for the antigenic structures defining the various blood groups which are sought before any blood transfusion.
- the process according to the invention uses the large areas of phospholipids and / or proteins present on the surface of a red cell, said zones not directly involved in the definition of blood groups and phenotypes.
- the red cells thus magnetized have the double property of being attracted under the effect of a magnetic field and of carrying on their surface the antigenic structures mentioned above. -above.
- the magnetized red blood cell will therefore be able to retain its expression properties of an antigenic structure while being mobile.
- markers and in particular red blood cells, are treated in such a way that their magnetic susceptibility is greatly increased, thus allowing them to migrate in a magnetic field created by a permanent magnet or an electromagnet.
- magnetic marking is not done by means of a magnetized probe molecule but by the use of particles interacting in a non-specific way with the red blood cell membrane so as to create a multitude of weak intensity bonds between the red blood cell surface and magnetic particles.
- magnetic particles are used which have the characteristics of having a very high homogeneity in size, in particular less than a micron and for example around 200 nm, a high load of ferromagnetic material for example around 75% by mass and a rather hydrophobic surface finish.
- the size of the markers is greater than that of the particles used to allow transfer into the magnetic field.
- These particles are attached to the surface of the red blood cell, for example by the intermediary of bovine serum albumin so as to create multiple non-specific bonds and low intensities between the surface of the red blood cell and the particles.
- the fixation takes place in two stages, the first consists in the activation of the particles so as to modify their surface state and the second is the bringing into contact of these activated particles with a suspension of red blood cells treated or not by proteolytic enzymes, so as to create non-specific bonds between particles and red cells.
- Activation can be carried out either immediately before contacting the marker or during manufacture.
- the red cells thus obtained are attracted by a magnetic field and can thus be used directly or, in a variant, treated with solutions of enzymes generally encountered in immuno-hematological tests.
- An embodiment of the method for magnetizing red cells without damaging the antigens which they carry is described below, in which the activation of the particles is carried out using a sticky substance comprising a solution of bovine albumin.
- Particles of type P201 from the company Ademtech are placed in the presence of a solution of bovine albumin at 0.1% (weight / volume) in PBS buffer pH 7.2. After an incubation of thirty minutes at room temperature and with shaking (proscribe any magnetic shaking), the particles in suspension are attracted by a magnet and the supernatant devoid of particles is eliminated.
- the “glued” particle pellet can be used directly during the red blood cell awareness phase.
- the activation of the particles can be carried out, optionally in addition to the action of a sticky substance, using a wetting agent or detergent such as cholic acid or Tween 20® so to modify the surface state of said particles.
- this activation can be carried out using electromagnetic radiation, such as gamma or UV radiation, which are known to modify plastic-type surfaces.
- Second step raising red blood cells
- the globular suspension buffered LISS Low lonic Strenght Solution
- the suspension After having perfectly homogenized the suspension (check that there are no more particle aggregates), it is incubated for 30 minutes at room temperature with stirring soft but homogeneous (the entire reaction volume must be set in motion).
- the red cells are then washed with a PBS buffer pH 7.4 (two washings by centrifugation, three minutes at 500 g).
- the pellet of sensitized red cells can then be taken up at the concentration for carrying out the analysis using a LISS buffer.
- the ratio between the quantity of particles used and the quantity of red blood cells is between 600 and 1000 so as to obtain sufficient magnetization without risking degrading the antigens present on the surface of the red blood cell.
- the surface occupied by the particles typically represents around 10% of the total surface of the red blood cell membrane.
- red cells sensitized by paramagnetic particles then have the double property of being attracted by a magnetic field and also of possessing on their surface blood antigens (group and phenotype). They can then be used as a reaction support and vector for transporting the antigen-antibody couple in an immunological analysis test.
- the red cells thus obtained can be used in tests of RAI type (Search for Irregular Agglutinins) either directly as a reagent or as an analyte, or undergo treatment with proteolytic enzymes such as papain to perform a so-called enzymatic analysis.
- RAI type Search for Irregular Agglutinins
- red cells having ferromagnetic particles on their surface giving them a paramagnetic property can be driven under the action of a magnetic force towards the reactive zone of a display device so as to allow the detection of directed antibodies. against antigenic determinants present on the surface of red blood cells. It is also possible to treat directly using the method described the red blood cells as an analyte of a blood sample to make them paramagnetic, and thus allow the migration of said red blood cells to an area capable of detecting the antigens that 'they support.
- particulate elements for example antibodies
- magnetized antibodies they can be used for training said red cells for example for their grouping.
- chemical markers can be treated so as to be made paramagnetic by means of a method analogous to that presented above.
- Such magnetized markers then have the dual property of being attracted under the effect of a magnetic field and of retaining a functional surface to allow the coupling of all kinds of chemical or biological molecules.
- the method of the invention allows direct magnetization of markers, and in particular of figured elements, without the use of covalently coupled molecules.
- the interaction between the particles and the markers is not final. There is therefore a possibility of finding the markers in their initial state after desorption of the particles. This desorption step can be carried out under mild conditions which do not alter the surface of the marker.
- the method also has the advantage of the speed and simplicity of setting up the interaction between the markers and the particles, simply under the influence of the probabilities of encountering the elements which have to interact.
- the particles used are non-organic products whose shelf life is very long and incommensurate with that of particles functionalized with organic products which are known to be highly unstable over time.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002217216A AU2002217216A1 (en) | 2000-12-08 | 2001-12-07 | Method for magnetising chemical or biological markers |
EP01999812A EP1342088A1 (fr) | 2000-12-08 | 2001-12-07 | Procede de magnetisation de marqueurs chimiques ou biologiques |
US10/433,852 US20040063163A1 (en) | 2000-12-08 | 2001-12-07 | Method for magnetising chemical or biological markers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0016026A FR2817967B1 (fr) | 2000-12-08 | 2000-12-08 | Procede de magnetisation de marqueurs chimiques ou biologiques |
FR0016026 | 2000-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002046758A1 true WO2002046758A1 (fr) | 2002-06-13 |
Family
ID=8857446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/003887 WO2002046758A1 (fr) | 2000-12-08 | 2001-12-07 | Procede de magnetisation de marqueurs chimiques ou biologiques |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040063163A1 (fr) |
EP (1) | EP1342088A1 (fr) |
AU (1) | AU2002217216A1 (fr) |
FR (1) | FR2817967B1 (fr) |
WO (1) | WO2002046758A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2869996A1 (fr) * | 2004-05-05 | 2005-11-11 | Diagast Soc Par Actions Simpli | Utilisation de ferrofluides pour le phenotypage sanguin et applications derivees |
WO2012010666A1 (fr) | 2010-07-21 | 2012-01-26 | Diagast | Méthodes d'immunodiagnostic magnétique et nécessaires révélant la présence de complexes anticorps/antigènes dans le cadre du groupage et du phénotypage du sang érythrocytaire |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2359689B1 (fr) | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Dispositif microfluidique pour la séparation de cellules et usage du dispositif |
CA2557819A1 (fr) * | 2004-03-03 | 2005-09-15 | The General Hospital Corporation | Dispositif magnetique destine a l'isolation de cellules et de biomolecules dans un environnement microfluidique |
US20070026417A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026415A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US20070026413A1 (en) * | 2005-07-29 | 2007-02-01 | Mehmet Toner | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
EP1874920A4 (fr) * | 2005-04-05 | 2009-11-04 | Cellpoint Diagnostics | Dispositifs et procédés permettant d'enrichir et de modifier des cellules tumorales circulantes et d'autres particules |
US20070026414A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070059680A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
US20070026416A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070059782A1 (en) * | 2005-09-13 | 2007-03-15 | Graham Henry A | Magnetic particle tagged blood bank reagents and techniques |
US9488665B2 (en) * | 2005-09-13 | 2016-11-08 | Chrome Red Technologies, Llc | Magnetic particle tagged reagents and techniques |
US20070059719A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Business methods for prenatal Diagnosis |
US20070059781A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for size based separation and analysis |
US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
US20070059774A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Kits for Prenatal Testing |
US20070059716A1 (en) * | 2005-09-15 | 2007-03-15 | Ulysses Balis | Methods for detecting fetal abnormality |
US20070059718A1 (en) * | 2005-09-15 | 2007-03-15 | Mehmet Toner | Systems and methods for enrichment of analytes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0351857A2 (fr) * | 1988-07-20 | 1990-01-24 | Olympus Optical Co., Ltd. | Méthode d'essai immunologique utilisant des particules magnétiques comme marqueurs |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267235A (en) * | 1979-03-19 | 1981-05-12 | California Institute Of Technology | Polyglutaraldehyde microspheres |
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4935147A (en) * | 1985-12-20 | 1990-06-19 | Syntex (U.S.A.) Inc. | Particle separation method |
DK641487A (da) * | 1987-12-07 | 1989-06-08 | Gluetech Aps | Fremgangsmaade til modificering af polymeroverflader |
AU4746590A (en) * | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
US5279936A (en) * | 1989-12-22 | 1994-01-18 | Syntex (U.S.A.) Inc. | Method of separation employing magnetic particles and second medium |
US5466609A (en) * | 1990-10-31 | 1995-11-14 | Coulter Corporation | Biodegradable gelatin-aminodextran particle coatings of and processes for making same |
WO1997046882A1 (fr) * | 1996-06-07 | 1997-12-11 | Immunivest Corporation | Separation magnetique au moyen de gradients externes et internes |
US5968820A (en) * | 1997-02-26 | 1999-10-19 | The Cleveland Clinic Foundation | Method for magnetically separating cells into fractionated flow streams |
-
2000
- 2000-12-08 FR FR0016026A patent/FR2817967B1/fr not_active Expired - Lifetime
-
2001
- 2001-12-07 EP EP01999812A patent/EP1342088A1/fr not_active Withdrawn
- 2001-12-07 AU AU2002217216A patent/AU2002217216A1/en not_active Abandoned
- 2001-12-07 US US10/433,852 patent/US20040063163A1/en not_active Abandoned
- 2001-12-07 WO PCT/FR2001/003887 patent/WO2002046758A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0351857A2 (fr) * | 1988-07-20 | 1990-01-24 | Olympus Optical Co., Ltd. | Méthode d'essai immunologique utilisant des particules magnétiques comme marqueurs |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2869996A1 (fr) * | 2004-05-05 | 2005-11-11 | Diagast Soc Par Actions Simpli | Utilisation de ferrofluides pour le phenotypage sanguin et applications derivees |
WO2005121805A3 (fr) * | 2004-05-05 | 2006-03-23 | Diagast | Utilisation de ferrofluides pour le phenotypage sanguin et applications derivees |
WO2012010666A1 (fr) | 2010-07-21 | 2012-01-26 | Diagast | Méthodes d'immunodiagnostic magnétique et nécessaires révélant la présence de complexes anticorps/antigènes dans le cadre du groupage et du phénotypage du sang érythrocytaire |
US9618518B2 (en) | 2010-07-21 | 2017-04-11 | Diagast | Magnetic immunodiagnostic methods and kit for the demonstration of antibody/antigen complexes in erythrocyte blood grouping and phenotyping |
Also Published As
Publication number | Publication date |
---|---|
FR2817967A1 (fr) | 2002-06-14 |
US20040063163A1 (en) | 2004-04-01 |
FR2817967B1 (fr) | 2003-02-28 |
EP1342088A1 (fr) | 2003-09-10 |
AU2002217216A1 (en) | 2002-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002046758A1 (fr) | Procede de magnetisation de marqueurs chimiques ou biologiques | |
Wu et al. | Application of nano-ELISA in food analysis: Recent advances and challenges | |
Yakovleva et al. | Microfluidic enzyme immunoassay using silicon microchip with immobilized antibodies and chemiluminescence detection | |
EP1957978B1 (fr) | Procede magnetique d'immunodiagnostic pour la mise en evidence de complexe anticorps/antigene, en particulier de groupe sanguin | |
CA2177288C (fr) | Dosage immunologique rapide permettant de detecter des anticorps ou des antigenes, comprenant l'extraction d'echantillon et la reaction immunogene simultanees | |
US4677067A (en) | Magnetotactic bacteria in clinical assay, immunoassay, and cell separation procedures and the like | |
EP1446666B1 (fr) | Methode de detection d'analyte(s) a l'aide de particules magnetiques colloidales | |
Otieno et al. | Bioconjugation of antibodies and enzyme labels onto magnetic beads | |
EP0041426B1 (fr) | Produit de couplage entre une lectine et un ligand spécifique, obtention et application dans le domaine biologique | |
JPH11246593A6 (ja) | 蛋白質および同類品の保護 | |
EP0239318A1 (fr) | Dosage avec emploi de membres d'une paire liante sur les particules et sur un filtre ou une membrane | |
FR2638848A1 (fr) | Procede de detection et/ou de dosage dans un milieu liquide ou semi-liquide d'au moins une substance organique, biologique ou medicamenteuse soluble, par une methode d'agglutination | |
Mulvaney et al. | Incorporating fluorescent dyes and quantum dots into magnetic microbeads for immunoassays | |
EP0179007A1 (fr) | Produits pour la séparation applicable à des cellules dans le domaine de l'immunopurification | |
CN101503734A (zh) | 生物分子高灵敏度检测方法 | |
FR2855613A1 (fr) | Procede de detection et de quantification multiplex d'analytes dans un echantillon a l'aide de microspheres | |
EP1344059B1 (fr) | Dispositif d'essai en continu, trousse de diagnostic comprenant ledit dispositif et utilisation de ce dispositif pour la detection d'un analyte dans un echantillon | |
EP1608978B1 (fr) | Procedes immunochromatographiques en phase solide | |
Kumar et al. | Magnetic capture from blood rescues molecular motor function in diagnostic nanodevices | |
US5085986A (en) | Diagnostic test kit and method for determination of chlamydial antigen using a membrane having surface hydroxy groups | |
JPS63314466A (ja) | 可逆的凝集メデイエーター | |
EP0389381B1 (fr) | Trousse et méthode de dosage enzymatique applicables à des cellules entières | |
US20150268234A1 (en) | Density Amplification in Magnetic Levitation to Detect Binding Events of Large Molecules | |
KR910700462A (ko) | 중합체 입자에 직접 결합시켜 단순포진 비루스 항원을 정량하는 방법 및 키트 | |
FR2656233A1 (fr) | Procede pour separer des constituants dans un melange. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001999812 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001999812 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10433852 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001999812 Country of ref document: EP |